HUE060152T2 - 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amin-származékok mint proteinkináz inhibitorok, elõállítási eljárásuk és gyógyászati alkalmazásuk - Google Patents

4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amin-származékok mint proteinkináz inhibitorok, elõállítási eljárásuk és gyógyászati alkalmazásuk

Info

Publication number
HUE060152T2
HUE060152T2 HUE16869945A HUE16869945A HUE060152T2 HU E060152 T2 HUE060152 T2 HU E060152T2 HU E16869945 A HUE16869945 A HU E16869945A HU E16869945 A HUE16869945 A HU E16869945A HU E060152 T2 HUE060152 T2 HU E060152T2
Authority
HU
Hungary
Prior art keywords
indol
pyrimidin
pyridin
preparation
protein kinase
Prior art date
Application number
HUE16869945A
Other languages
English (en)
Hungarian (hu)
Inventor
Lei Yin
Wenjian Liu
Heng Li
Dianxi Zhu
Original Assignee
Gan & Lee Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58796287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE060152(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan & Lee Pharmaceuticals filed Critical Gan & Lee Pharmaceuticals
Publication of HUE060152T2 publication Critical patent/HUE060152T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
HUE16869945A 2015-11-30 2016-11-28 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amin-származékok mint proteinkináz inhibitorok, elõállítási eljárásuk és gyógyászati alkalmazásuk HUE060152T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510856641.1A CN106810536A (zh) 2015-11-30 2015-11-30 一种蛋白激酶抑制剂及其制备方法和医药用途

Publications (1)

Publication Number Publication Date
HUE060152T2 true HUE060152T2 (hu) 2023-02-28

Family

ID=58796287

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16869945A HUE060152T2 (hu) 2015-11-30 2016-11-28 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amin-származékok mint proteinkináz inhibitorok, elõállítási eljárásuk és gyógyászati alkalmazásuk

Country Status (21)

Country Link
US (2) US11091476B2 (enExample)
EP (1) EP3385262B1 (enExample)
JP (2) JP6921101B2 (enExample)
KR (1) KR20180083421A (enExample)
CN (3) CN106810536A (enExample)
AU (1) AU2016365366B2 (enExample)
BR (1) BR112018010879A2 (enExample)
CA (1) CA3002884A1 (enExample)
CO (1) CO2018005854A2 (enExample)
DK (1) DK3385262T3 (enExample)
ES (1) ES2928169T3 (enExample)
HU (1) HUE060152T2 (enExample)
IL (1) IL259711B (enExample)
MA (1) MA42341B2 (enExample)
MX (1) MX387207B (enExample)
PH (1) PH12018550049A1 (enExample)
PT (1) PT3385262T (enExample)
RU (1) RU2749437C2 (enExample)
UA (1) UA124001C2 (enExample)
WO (1) WO2017092635A1 (enExample)
ZA (1) ZA201803531B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
US11440912B2 (en) 2017-10-27 2022-09-13 Fresenius Kabi Oncology Ltd Process for the preparation of ribociclib and its salts
BR112020015431A2 (pt) 2018-02-15 2020-12-08 Nuvation Bio Inc. Compostos heterocíclicos como inibidores de quinase
WO2019170055A1 (zh) * 2018-03-05 2019-09-12 上海海和药物研究开发有限公司 具有cdk4/6激酶抑制活性的化合物、其药用组合物和用途
SG11202108004VA (en) * 2019-01-29 2021-08-30 Beta Pharma Inc 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
EP3988545A1 (en) * 2019-06-21 2022-04-27 Gan & Lee Pharmaceuticals Co., Ltd. Methods for preparing cdk4/6 inhibitor and salt and intermediate thereof
AR119184A1 (es) * 2019-06-21 2021-12-01 Gan & Lee Pharmaceuticals Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas
WO2022042738A1 (zh) * 2020-08-31 2022-03-03 甘李药业股份有限公司 一种含cdk4/6抑制剂的药物组合物
CN116583283A (zh) * 2020-09-21 2023-08-11 普莱鲁德疗法有限公司 Cdk抑制剂及其作为药物的用途
US12129262B2 (en) 2020-12-18 2024-10-29 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
CN112390793B (zh) * 2021-01-19 2021-04-27 中国药科大学 Cdk6/dyrk2双靶点抑制剂及其制备方法和应用
WO2022218247A1 (zh) * 2021-04-12 2022-10-20 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物
WO2022242563A1 (zh) * 2021-05-17 2022-11-24 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
WO2023040914A1 (zh) * 2021-09-14 2023-03-23 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
CN118339157A (zh) * 2021-12-24 2024-07-12 江苏恒瑞医药股份有限公司 氢化吲哚类化合物、其制备方法及其在医药上的应用
CN115093397B (zh) * 2022-06-07 2023-09-05 自贡市第三人民医院 一种用于治疗肿瘤的化合物、合成方法及应用
CN117658987A (zh) * 2022-09-08 2024-03-08 上海深势唯思科技有限责任公司 作为plk1抑制剂的化合物及其制备方法和用途
CN119790049A (zh) * 2022-09-30 2025-04-08 楚浦创制（武汉）医药科技有限公司 2-氨基嘧啶类化合物及其应用、药用组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
SK12712002A3 (sk) 2000-02-07 2003-02-04 Abbott Gmbh & Co. Kg Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz
MEP46108A (en) * 2002-01-22 2011-02-10 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
WO2005076854A2 (en) * 2004-02-04 2005-08-25 Smithkline Beecham Corporation Pyrimidinone compounds useful as kinase inhibitors
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
WO2008124085A2 (en) * 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CA2715658C (en) * 2008-02-15 2016-07-19 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
RU2504545C2 (ru) 2008-05-16 2014-01-20 Ф. Хоффманн-Ля Рош Аг Ингибиторы jnk
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
EP3679043B9 (en) 2017-09-05 2023-09-27 Neumora Therapeutics, Inc. Vasopressin receptor antagonists and products and methods related thereto
WO2022218247A1 (zh) 2021-04-12 2022-10-20 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物

Also Published As

Publication number Publication date
US11091476B2 (en) 2021-08-17
JP6921101B2 (ja) 2021-08-18
ZA201803531B (en) 2021-10-27
KR20180083421A (ko) 2018-07-20
RU2749437C2 (ru) 2021-06-10
MX387207B (es) 2025-03-18
UA124001C2 (uk) 2021-07-07
US20210371418A1 (en) 2021-12-02
IL259711B (en) 2022-08-01
JP2019500413A (ja) 2019-01-10
EP3385262A4 (en) 2019-06-19
ES2928169T3 (es) 2022-11-15
JP2021138737A (ja) 2021-09-16
CN108290864B (zh) 2022-05-10
MA42341B2 (fr) 2021-05-31
PT3385262T (pt) 2022-10-18
DK3385262T3 (da) 2022-10-10
AU2016365366A1 (en) 2018-05-17
MA42341A1 (fr) 2018-06-29
CN108290864A (zh) 2018-07-17
MX2018006370A (es) 2018-09-24
CN106810536A (zh) 2017-06-09
RU2018122864A (ru) 2020-01-13
CO2018005854A2 (es) 2018-06-20
US20200165239A1 (en) 2020-05-28
EP3385262B1 (en) 2022-07-13
EP3385262A1 (en) 2018-10-10
CN113956238B (zh) 2023-07-14
CA3002884A1 (en) 2017-06-08
IL259711A (en) 2018-07-31
BR112018010879A2 (pt) 2018-11-21
AU2016365366B2 (en) 2021-03-04
CN113956238A (zh) 2022-01-21
RU2018122864A3 (enExample) 2020-03-17
WO2017092635A1 (zh) 2017-06-08
PH12018550049A1 (en) 2018-10-29
US11787801B2 (en) 2023-10-17

Similar Documents

Publication Publication Date Title
HUE060152T2 (hu) 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amin-származékok mint proteinkináz inhibitorok, elõállítási eljárásuk és gyógyászati alkalmazásuk
ZA201908609B (en) Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine
ZA201700652B (en) 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
IL252477B (en) History of 2-[(ethenyl-carbonyl-amino)anilino]-pyrimidine, process for their preparation and pharmaceutical preparations containing them
HK1246667A1 (zh) 作为jak抑制剂的2-(吡唑并吡啶-3-基)嘧啶衍生物
IL250447A0 (en) Stable and soluble formulations of receptor tyrosine kinase inhibitors and methods for their preparation
EP3115361A4 (en) Heterocyclic compounds, and preparation method and use thereof
HUE059672T2 (hu) Kinolinvegyületek, eljárás azok elõállítására, és urát transzporter inhibitor gyógyzserként történõ alkalmazásuk
DK3294449T3 (da) Pulverformigt titaniumoxid, fremgangsmåde til fremstilling deraf og anvendelse deraf
ZA201708568B (en) Pyrimidine derivatives as btk inhibitors and uses thereof
IL304547A (en) 3-substituted benzamide derivatives as kinase inhibitors
IL267829B (en) History of new amino-imidazopyridines as Janus kinase inhibitors and their pharmaceutical use
LT3196194T (lt) Pirimidino dariniai, tinkami naudoti kaip selektyvūs jak3 ir (arba) jak1 inhibitoriai
ZA201808014B (en) Adenine derivatives as protein kinase inhibitors
EP3176160A4 (en) Pyridine-substituted 2-aminopyridine protein kinase inhibitors
IL254152B (en) Pyrimidine derivatives as kinase inhibitors and their medicinal uses
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
EP3219311A4 (en) Pharmaceutical composition comprising dabigatran etexilate, and preparation method, solid preparation and use thereof
EP3175851A4 (en) Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition
ZA201908372B (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
IL237283A0 (en) Dldh and its derivatives, and preparations containing them for medical use
HK1240918A1 (en) 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof